Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS).


Chen R. W., Ansell S. M., Gallamini A., Connors J. M., Savage K. J., Collins G. P., ...Daha Fazla

JOURNAL OF CLINICAL ONCOLOGY, cilt.36, sa.15, 2018 (SCI-Expanded) identifier